Genedx Holdings CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Casdin Partners Master Fund acquired 500,000 shares of GeneDx Holdings Corp. between May 18 and May 20, 2026.
NASDAQ
Corvex Management LP and affiliated entities have increased their stake in GeneDx Holdings Corp. through open market purchases.
NASDAQ
Key investors Eli Casdin and Keith Meister, through their respective entities, have significantly increased their beneficial ownership in GeneDx Holdings Corp.
NASDAQ
A group including Eli Casdin and Keith Meister reported a reduction in their beneficial ownership of GeneDx Holdings Corp. Class A common stock through an open market sale.
NASDAQ
SCHEDULE 13D/A: Key Investors Increase Stake in GeneDx Holdings Corp., Boosting Beneficial Ownership
A group of significant investors, including Eli Casdin and Keith Meister, have increased their beneficial ownership in GeneDx Holdings Corp., with their collective stake now reaching up to 14.2% of Class A common stock.
NASDAQ
SCHEDULE 13D/A: Mount Sinai Entities Divest Significant Stake in GeneDx Holdings, Ceasing 5% Beneficial Ownership
Icahn School of Medicine at Mount Sinai and Mount Sinai Health System, Inc. have completed sales of GeneDx Holdings Corp. Class A Common Stock, reducing their collective beneficial ownership below 5% and filing their final Schedule 13D amendment.
NASDAQ
Icahn School of Medicine at Mount Sinai (ISMMS) has significantly reduced its beneficial ownership in GeneDx Holdings Corp. through a series of stock sales in early 2025.